Anastrozole Tablets — Class II drug recall D-1441-2019
Terminated recall by Zydus Pharmaceuticals USA Inc, reported 2019-06-26, distributed nationwide. CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.
| Recall number | D-1441-2019 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Zydus Pharmaceuticals USA Inc, Pennington, NJ, United States |
| Recall initiated | 2019-05-06 |
| Classified | 2019-07-01 |
| Reported by FDA | 2019-06-26 |
| Terminated | 2021-09-16 |
| Distributed | Nationwide (US) |
| Reason classes | cgmp |
| NDC | 68382-0209, 68382-0209-06, 68382-0209-10 |
| Lot numbers | AUG-20, FEB-20, JUN-19, M708570, M711270, M802207, M812460, SEP-19 |
Product
Anastrozole Tablets, USP, 1 mg, 1,000-count bottle, Rx only, Manufactured by: Cadila Healthcare Ltd. Ahmedabad, India Distributed by: Zydus Pharmaceuticals (USA) Inc. Pennington, NJ 08534. NDC 68382-209-10
Reason for recall
CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1441-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.